These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 30140882)
1. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. Kim JJ; Burger EA; Regan C; Sy S JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882 [TBL] [Abstract][Full Text] [Related]
2. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883 [TBL] [Abstract][Full Text] [Related]
3. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884 [TBL] [Abstract][Full Text] [Related]
4. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. Sawaya GF; Sanstead E; Alarid-Escudero F; Smith-McCune K; Gregorich SE; Silverberg MJ; Leyden W; Huchko MJ; Kuppermann M; Kulasingam S JAMA Intern Med; 2019 Jul; 179(7):867-878. PubMed ID: 31081851 [TBL] [Abstract][Full Text] [Related]
5. Primary cervical screening with high risk human papillomavirus testing: observational study. Rebolj M; Rimmer J; Denton K; Tidy J; Mathews C; Ellis K; Smith J; Evans C; Giles T; Frew V; Tyler X; Sargent A; Parker J; Holbrook M; Hunt K; Tidbury P; Levine T; Smith D; Patnick J; Stubbs R; Moss S; Kitchener H BMJ; 2019 Feb; 364():l240. PubMed ID: 30728133 [TBL] [Abstract][Full Text] [Related]
6. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. Kim JJ; Burger EA; Sy S; Campos NG J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Munshi VN; Perkins RB; Sy S; Kim JJ Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295 [TBL] [Abstract][Full Text] [Related]
8. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. Kulasingam SL; Havrilesky LJ; Ghebre R; Myers ER J Low Genit Tract Dis; 2013 Apr; 17(2):193-202. PubMed ID: 23519288 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial. Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. Ting J; Smith JS; Myers ER J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462 [TBL] [Abstract][Full Text] [Related]
12. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study. Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537 [TBL] [Abstract][Full Text] [Related]
13. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648 [TBL] [Abstract][Full Text] [Related]
14. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China. Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972 [TBL] [Abstract][Full Text] [Related]
15. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518 [TBL] [Abstract][Full Text] [Related]
16. Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing. Malagón T; Mayrand MH; Ogilvie G; Gotlieb WH; Blake J; Bouchard C; Franco EL; Kulasingam S Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1436-1446. PubMed ID: 32332032 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening. Harper DM; Anderson RJ; Baker E; Yu TM Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751 [TBL] [Abstract][Full Text] [Related]